1. Home
  2. BAOS vs IMNN Comparison

BAOS vs IMNN Comparison

Compare BAOS & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Baosheng Media Group Holdings

BAOS

Baosheng Media Group Holdings

N/A

Current Price

$0.24

Market Cap

9.1M

ML Signal

N/A

Logo Imunon Inc.

IMNN

Imunon Inc.

N/A

Current Price

$1.31

Market Cap

7.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BAOS
IMNN
Founded
2018
1982
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.1M
7.9M
IPO Year
2020
2000

Fundamental Metrics

Financial Performance
Metric
BAOS
IMNN
Price
$0.24
$1.31
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $17.00
AVG Volume (30 Days)
★ 4.6M
133.7K
Earning Date
04-30-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$1.28
52 Week High
$5.21
$5.55

Technical Indicators

Market Signals
Indicator
BAOS
IMNN
Relative Strength Index (RSI) 29.04 34.41
Support Level N/A N/A
Resistance Level $0.36 $1.59
Average True Range (ATR) 0.03 0.11
MACD 0.03 -0.01
Stochastic Oscillator 14.75 3.23

Price Performance

Historical Comparison
BAOS
IMNN

About BAOS Baosheng Media Group Holdings

Baosheng Media Group Holdings Ltd is a China-based online marketing solution provider. The company provides internet marketing, short-video and V-log marketing, content production and operation, e-commerce marketing, data platform services, and AI technology-related services. It also offers customized marketing solutions and channel marketing services through partnerships with internet platforms such as Tencent, Alibaba, ByteDance, and Kuaishou.

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.

Share on Social Networks: